Multiple pseudoprogressions during ongoing immunotherapy-based treatment of advanced gastric neuroendocrine carcinoma: A case report and review of literature

Figure 2 Serial computed tomography images. A: Images of the abdomen with recurrence; B: Images taken during the first pseudoprogression (PsP) episode of liver lesions after two cycles of teprotumumab (240 mg q3w) combined with sulfatinib (300 mg/day); C: Images of the reduction of the liver lesion after two cycles of treatment; D: Images of the enlarged liver lesion during the second PsP episode after six months of treatment with teprotumumab (240 mg q3w) combined with sulfatinib (300 mg/day); E: Images of the decrease in liver lesion after a subsequent one cycle of treatment.